Korea Launches Low-Cost Drug Discovery Platform

Finding new medicines just got faster and cheaper for researchers in South Korea. The Korea Research Institute of Chemical Technology has launched a public platform that can test tens of millions of potential drug compounds in under a month, a process that previously took at least two months and cost significantly more.

The breakthrough centers on DNA-encoded library technology, which works like a molecular matching game. Instead of testing each chemical compound separately in individual wells, researchers attach unique DNA barcodes to different chemical building blocks and combine them to create millions of compounds all at once.

Think of it like LEGO blocks. Combine one set of 100 blocks with another set of 100, and you get 10,000 unique combinations. Repeat that process a few times, and suddenly you have tens of millions of distinct compounds swimming in a single test tube.

When researchers add disease-related proteins to this mixture, only certain compounds stick to them. Scientists then use gene sequencing technology to read which DNA barcodes attached to the proteins, revealing which compounds might work as medicines.

The platform even uses artificial intelligence to spot patterns and filter out false positives. The AI analyzes real experimental data to identify the top 50 compounds most likely to become effective drugs, reducing errors that happen when random impurities interfere with results.

Why This Inspires

Korean researchers previously had to rely on expensive overseas companies, often in China, for this kind of drug discovery work. That meant higher costs and potential concerns about protecting sensitive research data.

Now institutions like Daewoong Pharmaceutical, the National Cancer Center, and several universities are already using the platform. Through 2027, the government is offering 50% discounts on service fees, making cutting-edge drug discovery accessible to more researchers who might lack big pharmaceutical budgets.

The technology matters because drug development starts with screening thousands or millions of compounds to find ones that might fight diseases. Making this process faster and cheaper means more shots on goal for discovering treatments for cancer, rare diseases, and other conditions that need new therapies.

Every month saved in early drug discovery could eventually mean patients getting new treatments sooner, and every dollar saved is money that can go toward additional research instead of expensive screening fees.

South Korea now joins the small group of countries offering this advanced drug discovery technology domestically, turning what was once a dependency into homegrown scientific capability that serves researchers across the nation.